Cite

HARVARD Citation

    Asnaghi, V. et al. (n.d.). [O2–17–06]: SAFETY AND TOLERABILITY OF CRENEZUMAB IN MILD‐TO‐MODERATE AD PATIENTS TREATED WITH ESCALATING DOSES FOR UP TO 25 MONTHS. Alzheimer's & dementia. p. P602. [Online]. 
  
Back to record